February 2026—Natera has completed a transaction to acquire cancer diagnostics company Foresight Diagnostics. The transaction combines Natera’s commercial and operational infrastructure for the delivery of personalized molecular residual disease testing with Foresight’s phased variant technology and focus on lymphoma testing. Foresight’s circulating tumor DNA–based MRD tests leverage its patented PhasED-Seq technology, targeting phased variants.
Natera has closed the acquisition of Foresight in an all-stock transaction consisting of $275 million up front with an additional $175 million in earn outs tied to the achievement of revenue- and reimbursement-based milestones.
Natera, 650-489-9050